NCT02315027View on ClinicalTrials.gov

Mesenchymal Stem Cell Therapy in Multiple System Atrophy

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
MSA
Interventions
BIOLOGICAL

Autologous Mesenchymal Stem Cells

single dose of 1 × 10(7) cells intrathecally

BIOLOGICAL

Autologous Mesenchymal Stem Cells

2 doses of 5 × 10(7) cells intrathecally each 1 month (±4 days) apart

BIOLOGICAL

Autologous Mesenchymal Stem Cells

2 doses of 1 × 10(8) cells intrathecally each 1 month apart

BIOLOGICAL

Autologous Mesenchymal Stem Cells

Ten doses of 5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart

BIOLOGICAL

Autologous Mesenchymal Stem Cells

Ten doses of 2.5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Mayo Clinic

OTHER